Abstract:1194 Objectives The presence of the gastrin-releasing peptide receptor (GRPR) has been documented in many human cancers including prostate cancer (Pca), breast cancer and lung cancer. Bombesin (BBN) peptide, an amphibian homologue of mammalian GRP, has demonstrated the ability to bind with high affinity and specificity to GRPR. Although a variety of BBN peptides and their analogs, including both agonists and antagonists, have been widely investigated as GRPR targeted imaging probes for cancer imaging in animal models and patients, a PET probe with better performance is still highly desired for clinical applications. In this work, we aim to develop a GRPR targeted PET probe with high clinical translation ability. A novel BBN analogs which contains an 8-amino octanoic acid spacer (named as ZY1) was thus designed and conjugated with the metal chelator NODAGA. The resulting NODAGA-ZY1 was radiolabeled with 68Ga and evaluated for PET imaging of PCa. Methods Synthesis of the ZY1 was done using standard Fmoc solid-phase peptide chemistry, and the NODAGA conjugation was performed using standard coupling reaction. The NODAGA-ZY1 was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. For in-vitro characterization, receptor binding assay was performed to measure the binding affinity of the peptide using 125I-Tyr4-BBN as a radioligand. The competitive uptake and blocking studies in PC-3 cells and serum stability were further accomplished. To characterize the tumor targeting properties, in vivo static PET/CT-imaging at multiple time points (0.5, 1, and 2 h) and ex-vivo biodistribution to specific organs collected after sacrifice at 2 h post-injection were performed for 68Ga-NODAGA-ZY1 and a comparison probe 68Ga-NODAGA-RM1 in PC-3 tumor-bearing nude mice (n=4 per group). Blocking study with large excess of BBN peptides was also accomplished. Results 68Ga-labeling gave high yield (>98 %) with high purity (>98 %) determined by HPLC. The binding affinity of NODAGA-ZY1 was measured to be 1.30±0.35 nM. The radiolabeled probe was stable after 2 hour serum incubation and showed specific uptake in PC-3 cells. Static PET/CT-imaging demonstrated that tumor was clearly imaged with high tumor to background contrast at 0.5, 1 and 2 h post-injection of 68Ga-NODAGA-ZY1. Quantification analysis of PET images revealed that tumor uptake of the probe was 4.64±0.40%, 5.30±0.41 and 5.80±0.42 %ID/g at 0.5, 1 and 2 h post-injection of the probe, respectively. In comparison, for contol group injected with 68Ga-NODAGA-RM1, much lower tumor PET signals were observed at all-time points. The tumor to background ratio (T/N) ratios for both probes were significantly higher than those of the blocking groups. Importantly, the T/N was 17.66±2.47 at 2 h time point for 68Ga-NODAGA-ZY1 , which was nearly two times of the control group with the T/N value of 9.42±1.39. Ex-vivo biodistribution performed at 2 h post-injection also verified the relative low accumulation in the liver (4.21±0.42 %ID/g) and kidney (3.41±0.46 %ID/g), which suggested that the clearance routes of 68Ga-NODAGA-ZY1 were through hepatobiliary and renal systems. Furthermore, much lower tumor uptake of 68Ga-NODAGA-ZY1 was obtained (0.77±0.08 %ID/g at 2 h) in the presence of the blocking peptide, indicating the specific targeting properties of this probe. Conclusions A novel GRPR targeted 68Ga-NODAGA-ZY1 has been facile prepared. In vitro assay and in vivo studies highlight that 68Ga-NODAGA-ZY1 exhibits high stability, binding affinity, specificity, and excellent in vivo tumor imaging properties. It represents a highly promising probe for the PET imaging of PCa for clinical applications.

A Heterodimeric [Rgd-Glu-[(64)cu-no2a]-6-ahx-rm2] Αvβ3/grpr-Targeting Antagonist Radiotracer for PET Imaging of Prostate Tumors.

Novel 64 Cu Labeled RGD 2 -BBN Heterotrimers for PET Imaging of Prostate Cancer.

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging

177Lu-Labeled RGD-BBN Heterodimeric Peptide for Targeting Prostate Carcinoma

Evaluation of A Cu-64-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for Pet of Tumors Expressing Alpha(V)Beta(3) Integrin

18F, 64Cu, and68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer

Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer

18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging

Development A Clinical Translatable 68Ga-Labeled and Grpr-Targeted Probe for Pet Imaging of Prostate Cancer

Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist

Two Novel [ 68 Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar 11 ]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03

Development of [18f] Alf-Nota-Rgd2 Probe for Micropet Imaging in U87mg-Tumor Bearing Mice

Improving Tumor Uptake and Pharmacokinetics of (64)Cu-Labeled Cyclic RGD Peptide Dimers with Gly(3) and PEG(4) Linkers.

A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer

Evaluation of 188Re-Mag2-rgd-bombesin for Potential Prostate Cancer Therapy

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Bombesin peptoids and peptides based PET probes for prostate cancer imaging

Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors